BISPECIFIC MONOCLONAL ANTIBODY CAPABLE OF CROSS REACTING WITH LETHAL FACTOR (LF) AND EDEMA FACTOR (EF), AND NEUTRALIZING EDEMA TOXIN (ET) AS WELL AS LETHAL TOXIN (LT) OF BACILLUS ANTHRACIS
The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of B. anthracis. It also relates to process for preparation of said mAb, and to pharmaceutical preparations, anthrax diagnostic tool, in-vivo diagnostic imaging tool comprising said mAb. It also relates to genetically modified mAb, and method for prophylaxis against anthrax disease comprising administration of mAb or genetically modified mAb of present invention.
